Is Sarepta Therapeutics, Inc. (SRPT) The Best Fast Growth Stock To Buy Right Now?
We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
BioPharma Dive2d
Solid says early data suggest ‘differentiated’ Duchenne gene therapy
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Biogen continues dealmaking buzz with Stoke Therapeutics
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
STAT2d
Duchenne gene therapy from Solid Biosciences produces promising results in early study
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
Hosted on MSN3d
Down -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a Turnaround
Sarepta Therapeutics (SRPT) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over ...
State of Alaska Department of Revenue Sells 145 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
Managed Healthcare Executive8d
Sarepta Announces Positive Results for Elevidys, Gene Therapy for Duchenne
Results show improved functional outcomes for people with Duchenne muscular dystrophy who are ambulatory. Elevidys, which is ...
standard-journal8d
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market ...